Synagis Palivizumab

Synagis, also known as palivizumab, is used to prevent serious respiratory infections caused by the respiratory syncytial virus (RSV) in infants and young children who are at high risk for severe illness. It is given as a monthly injection and is most commonly used for premature babies and those with certain preexisting medical conditions such as heart and lung diseases, weakened immune systems, and infants with Down syndrome. Synagis works by providing passive immunity to RSV, making it harder for the virus to cause serious illness in the child.